Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Naba Alsaha Medical Services CoSAU:9546 58 EBITDA Margin % is 15.99% as of Dec. 2025, which is 42% below its 10-year median of 27.79. GuruFocus rates SAU:9546 with a GF Score™ of 58/100 and a GF Value™ of ﷼42.04 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 665 Healthcare Providers & Services companies, Naba Alsaha Medical Services Co ranks better than 63.61% on this metric.
Naba Alsaha Medical Services Co (SAU:9546) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Naba Alsaha Medical Services Co EBITDA Margin % Related Terms
Naba Alsaha Medical Services Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Naba Alsaha Medical Services Co EBITDA Margin % Chart
SAU:9546 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Naba Alsaha Medical Services Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naba Alsaha Medical Services Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Naba Alsaha Medical Services Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Naba Alsaha Medical Services Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Naba Alsaha Medical Services Co (SAU:9546) has a EBITDA Margin % of 15.99% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Naba Alsaha Medical Services Co and its competitors. This is 42% below median its historical median of 27.79. Over the past decade, Naba Alsaha Medical Services Co's EBITDA Margin % has ranged from 15.65 to 35.63. According to the industry distribution chart, Naba Alsaha Medical Services Co ranks #242 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 36.4%.
Is Naba Alsaha Medical Services Co's EBITDA Margin % too high?
Naba Alsaha Medical Services Co's current EBITDA Margin % of 15.99% is 42% below median its 10-year median of 27.79. Over the past 10 years, this metric has ranged from a low of 15.65 to a high of 35.63. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Naba Alsaha Medical Services Co's value of 15.99% is 56.2% above this industry median. Based on the distribution chart, Naba Alsaha Medical Services Co ranks #242 out of 665 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Naba Alsaha Medical Services Co has a GF Score™ of 58/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Naba Alsaha Medical Services Co's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Naba Alsaha Medical Services Co ranks #242 out of 665 companies for EBITDA Margin %. This puts Naba Alsaha Medical Services Co in the upper half of its industry. The industry median EBITDA Margin % is 10.24. Naba Alsaha Medical Services Co's value of 15.99% is 56.2% above this benchmark. Historically, Naba Alsaha Medical Services Co's own EBITDA Margin % has ranged from 15.65 to 35.63 over the past decade. While the company's 10-year median is 27.79 vs. the industry median of 10.24, Naba Alsaha Medical Services Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Naba Alsaha Medical Services Co's current EBITDA Margin % of 15.99% is 56.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Naba Alsaha Medical Services Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Naba Alsaha Medical Services Co's current EBITDA Margin % is 15.99%, which is 42% below median its own 10-year median of 27.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naba Alsaha Medical Services Co stock overvalued right now?
Based on GuruFocus' analysis, Naba Alsaha Medical Services Co (SAU:9546) is currently considered Significantly Undervalued. The stock's GF Value™ is ﷼42.04, compared to a current price of ﷼21.38 — trading 49.1% below its estimated fair value. The current EBITDA Margin % is 15.99%, which is 42% below median its 10-year median of 27.79 and 56.2% above the Healthcare Providers & Services industry median of 10.24. Naba Alsaha Medical Services Co's overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Naba Alsaha Medical Services Co (SAU:9546), the current EBITDA Margin % is 15.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naba Alsaha Medical Services Co (SAU:9546) Overvalued in 2026?
Based on GuruFocus' analysis, Naba Alsaha Medical Services Co stock appears to be undervalued.
The current stock price of ﷼21.38 is trading 49.1% below its estimated GF Value™ of ﷼42.04.
GuruFocus considers Naba Alsaha Medical Services Co to be Significantly Undervalued.
Key valuation signals for SAU:9546:
EBITDA Margin %: 15.99% (42% below median its 10-year median of 27.79)
GF Value™: ﷼42.04 vs. price of ﷼21.38 (49.1% below fair value)
Industry Position: 56.2% above the Healthcare Providers & Services median (#242 of 665)
No single metric tells the full story. See the SAU:9546 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naba Alsaha Medical Services Co Business Description
Naba Alsaha Medical Services Co is engaged in the medical operation of private and government hospitals, health facilities, and hospital-related activities. It operates and manages Al-Zahraa Hospital, Manarat Al-Haramain Pharmacy, and the Nabaa Al-Saha branch for the practice of maintenance work and the operation of buildings. Geographically, it operates in the Kingdom of Saudi Arabia.
58GF Score
Get the complete analysis for SAU:9546
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:9546 has been successfully added to your 
